Abstracts tagged "nanomedicine"

Abstract Number: 2704 • 2017 ACR/ARHP Annual Meeting
Skin Migratory Dendritic Cells Targeted and Tolerized By Calcitriol-Peptide Liposomes Supress Antigen-Specific Autoreactive T Cell Expansion and Memory Differentiation to Regulate Autoimmune Arthritis
Ryan Galea^1,2, Hendrik Nel^1,2, Meghna Talekar^1,2, Suzanne Cole³, Karyn Cochlin⁴, Shannon Hitchcock⁵, Bijun Zeng^1,2, Suman Yekollu^1,2, Jamie Rossjohn⁶, Hugh Reid⁷, Ravi Malaviya⁵, Dave Shealy⁸, Brendan O'Sullivan^1,2 and Ranjeny Thomas^1,2, ¹Dendright Pty Ltd, Brisbane, Australia, ²University of Queensland Diamantina Institute, Brisbane, Australia, ³Immunology, Janssen Research and Development, Spring House, PA, ⁴Immunology, Janssen Research and Development, Springhouse, PA, ⁵Janssen Research and Development, Springhouse, PA, ⁶Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ⁷Monash University, Melbourne, Australia, ⁸Janssen Research and Development, Spring House, PA
Background/Purpose: Current treatments to control autoimmune arthritis and vasculitis use broadly immunosuppressive drugs, associated with undesirable side effects. Antigen-specific immunological tolerance strategies are preferable to…
Abstract Number: 2317 • 2013 ACR/ARHP Annual Meeting
Impact of PVA Coated Nanoparticles On Cellular Viability and Functionality of Immune Cells Obtained From Healthy Donors and Patients With Rheumatoid Arthritis Or Osteoarthritis
Cindy Strehl¹, Timo Gaber¹, Manuela Jakstadt¹, Martin Hahne¹, Saskia Schellmann¹, Barbara Szostak¹, Géraldine Coullerez², Heinrich Hofmann², Gerd Burmester³ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Institute of Materials Powder Technology Laboratory, École polytechnique fédérale de Lausanne, Lausanne, Switzerland, ³Rheumatology and Clinical Immunology, Campus Mitte, Charite University Hospital, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Nanotechnology has developed into a key technology of the 21st century. Over the recent years, the number of nanotechnical products has received an enormous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].